Abstract | INTRODUCTION: Even though cognitive impairment is manifested in almost all patients with schizophrenia, the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) study showed no significant difference between first- and second-generation psychotropic drugs in improving cognitive abilities. Discovering new drugs that can improve impaired cognition, thus, is an attractive treatment target for patients with schizophrenia. AREAS COVERED: EXPERT OPINION: The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option. While longer randomized controlled trials, increase dosage and selected groups of patients at different stage of cognitive impairment may provide a better understanding of the potential for this drug in addressing cognitive deficits, results to date have not been encouraging.
|
Authors | Neelam Thakurathi, Brenda Vincenzi, David C Henderson |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 22
Issue 2
Pg. 259-65
(Feb 2013)
ISSN: 1744-7658 [Electronic] England |
PMID | 23215841
(Publication Type: Journal Article, Review)
|
Chemical References |
- Cholinesterase Inhibitors
- Indans
- Piperidines
- Donepezil
|
Topics |
- Binding Sites
- Cholinesterase Inhibitors
(administration & dosage, chemistry, pharmacology, therapeutic use)
- Clinical Trials as Topic
- Cognition Disorders
(drug therapy, psychology)
- Donepezil
- Humans
- Indans
(administration & dosage, chemistry, pharmacology, therapeutic use)
- Models, Molecular
- Molecular Structure
- Piperidines
(administration & dosage, chemistry, pharmacology, therapeutic use)
- Schizophrenia
(complications, drug therapy)
- Schizophrenic Psychology
- Treatment Outcome
|